These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31397525)

  • 61. Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.
    Chheda ZS; Kohanbash G; Okada K; Jahan N; Sidney J; Pecoraro M; Yang X; Carrera DA; Downey KM; Shrivastav S; Liu S; Lin Y; Lagisetti C; Chuntova P; Watchmaker PB; Mueller S; Pollack IF; Rajalingam R; Carcaboso AM; Mann M; Sette A; Garcia KC; Hou Y; Okada H
    J Exp Med; 2018 Jan; 215(1):141-157. PubMed ID: 29203539
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [HLA-restricted cancer-specific killer T cells].
    Harada M; Itoh K
    Nihon Rinsho; 2005 Apr; 63 Suppl 4():579-84. PubMed ID: 15861714
    [No Abstract]   [Full Text] [Related]  

  • 63. The Role of Mass Spectrometry and Proteogenomics in the Advancement of HLA Epitope Prediction.
    Creech AL; Ting YS; Goulding SP; Sauld JFK; Barthelme D; Rooney MS; Addona TA; Abelin JG
    Proteomics; 2018 Jun; 18(12):e1700259. PubMed ID: 29314742
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A library of Neo Open Reading Frame peptides (NOPs) as a sustainable resource of common neoantigens in up to 50% of cancer patients.
    Koster J; Plasterk RHA
    Sci Rep; 2019 Apr; 9(1):6577. PubMed ID: 31036835
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Neoepitopes-based vaccines: challenges and perspectives.
    Alcazer V; Bonaventura P; Tonon L; Wittmann S; Caux C; Depil S
    Eur J Cancer; 2019 Feb; 108():55-60. PubMed ID: 30648630
    [TBL] [Abstract][Full Text] [Related]  

  • 66. DeepHLApan: A Deep Learning Approach for the Prediction of Peptide-HLA Binding and Immunogenicity.
    Wu J; Li J; Chen S; Zhou Z
    Methods Mol Biol; 2024; 2809():237-244. PubMed ID: 38907901
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
    Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
    Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
    [TBL] [Abstract][Full Text] [Related]  

  • 68. ProGeo-Neo v2.0: A One-Stop Software for Neoantigen Prediction and Filtering Based on the Proteogenomics Strategy.
    Liu C; Zhang Y; Jian X; Tan X; Lu M; Ouyang J; Liu Z; Li Y; Xu L; Chen L; Lin Y; Xie L
    Genes (Basel); 2022 Apr; 13(5):. PubMed ID: 35627168
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Noncoding regions are the main source of targetable tumor-specific antigens.
    Laumont CM; Vincent K; Hesnard L; Audemard É; Bonneil É; Laverdure JP; Gendron P; Courcelles M; Hardy MP; Côté C; Durette C; St-Pierre C; Benhammadi M; Lanoix J; Vobecky S; Haddad E; Lemieux S; Thibault P; Perreault C
    Sci Transl Med; 2018 Dec; 10(470):. PubMed ID: 30518613
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Genome-scale search of tumor-specific antigens by collective analysis of mutations, expressions and T-cell recognition.
    Jia J; Cui J; Liu X; Han J; Yang S; Wei Y; Chen Y
    Mol Immunol; 2009 May; 46(8-9):1824-9. PubMed ID: 19243822
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Translating Immunopeptidomics to Immunotherapy-Decision-Making for Patient and Personalized Target Selection.
    Fritsche J; Rakitsch B; Hoffgaard F; Römer M; Schuster H; Kowalewski DJ; Priemer M; Stos-Zweifel V; Hörzer H; Satelli A; Sonntag A; Goldfinger V; Song C; Mahr A; Ott M; Schoor O; Weinschenk T
    Proteomics; 2018 Jun; 18(12):e1700284. PubMed ID: 29505699
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes.
    Chong C; Müller M; Pak H; Harnett D; Huber F; Grun D; Leleu M; Auger A; Arnaud M; Stevenson BJ; Michaux J; Bilic I; Hirsekorn A; Calviello L; Simó-Riudalbas L; Planet E; Lubiński J; Bryśkiewicz M; Wiznerowicz M; Xenarios I; Zhang L; Trono D; Harari A; Ohler U; Coukos G; Bassani-Sternberg M
    Nat Commun; 2020 Mar; 11(1):1293. PubMed ID: 32157095
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Lack of detectable neoantigen depletion signals in the untreated cancer genome.
    Van den Eynden J; Jiménez-Sánchez A; Miller ML; Larsson E
    Nat Genet; 2019 Dec; 51(12):1741-1748. PubMed ID: 31768072
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Nonclassical HLA-G molecules are classical peptide presenters.
    Diehl M; Münz C; Keilholz W; Stevanović S; Holmes N; Loke YW; Rammensee HG
    Curr Biol; 1996 Mar; 6(3):305-14. PubMed ID: 8805247
    [TBL] [Abstract][Full Text] [Related]  

  • 76. TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis.
    Wu J; Zhao W; Zhou B; Su Z; Gu X; Zhou Z; Chen S
    Genomics Proteomics Bioinformatics; 2018 Aug; 16(4):276-282. PubMed ID: 30223042
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Dermatophagoides farinae-1-derived peptides and HLA molecules recognized by T cells from atopic individuals.
    Matsuoka T; Kohrogi H; Ando M; Nishimura Y; Matsushita S
    Int Arch Allergy Immunol; 1997 Apr; 112(4):365-70. PubMed ID: 9104792
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Population-level distribution and putative immunogenicity of cancer neoepitopes.
    Wood MA; Paralkar M; Paralkar MP; Nguyen A; Struck AJ; Ellrott K; Margolin A; Nellore A; Thompson RF
    BMC Cancer; 2018 Apr; 18(1):414. PubMed ID: 29653567
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Influence of T Cell-Mediated Immune Surveillance on Somatic Mutation Occurrences in Melanoma.
    Jiang C; Schaafsma E; Hong W; Zhao Y; Zhu K; Chao CC; Cheng C
    Front Immunol; 2021; 12():703821. PubMed ID: 35111147
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Human tumor-rejection antigens and peptides from genes to clinical research].
    Itoh K; Yamana H; Shichijo S; Yamada A
    Nihon Geka Gakkai Zasshi; 2000 Sep; 101(9):612-7. PubMed ID: 11022676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.